Search research articles
Contact Us
Filters
Showing results (1-10 of 205) with videos related to
Page
of 21
Sort By:
Gut
|
March 13, 2012
The multiple effects of tumour necrosis factor inhibitors on immune cells: new insights on inhibition of activation and cycling
Matthieu Allez
Gastroenterology
|
August 5, 2022
A CEACAM5-derived Peptide Activating CD8<sup>+</sup> Regulatory T Cells: A Future Option for Restoring Mucosal Homeostasis in Crohn's Disease?
Matthieu Allez
La Revue Du Praticien
|
February 24, 2005
[Crohn's disease and ulcerative colitis]
Marc Lémann, Matthieu Allez
La Revue Du Praticien
|
August 2, 2005
[Treatment strategies for inflammatory bowel disease]
Marc Lémann, Matthieu Allez
The American Journal of Gastroenterology
|
September 7, 2017
Response to Dhoble et al
Mathurin Fumery, Matthieu Allez
World Journal of Gastroenterology
|
June 3, 2010
Role of endoscopy in predicting the disease course in inflammatory bowel disease
Matthieu Allez, Marc Lémann
Current Drug Targets
|
March 10, 2010
Efficacy of anti-TNF in Crohn's disease: how does it work?
Yehuda Chowers, Matthieu Allez
Alimentary Pharmacology & Therapeutics
|
March 13, 2023
Editorial: severe colitis induced by targeted therapies in dermato-oncology beyond check point-inhibitors
Nassim Hammoudi, Matthieu Allez
The Lancet. Gastroenterology & Hepatology
|
February 15, 2025
Vedolizumab for prevention of recurrence of Crohn's disease
Nassim Hammoudi, Matthieu Allez
Current Opinion in Gastroenterology
|
June 4, 2015
Complications of biologics in inflammatory bowel disease
Paula Sousa, Matthieu Allez
Page
of 21
Search research articles
Search
Showing results (1-10 of 205) with videos related to
Sort By:
Page
of 21
Gut
|
March 13, 2012
The multiple effects of tumour necrosis factor inhibitors on immune cells: new insights on inhibition of activation and cycling
Matthieu Allez
Gastroenterology
|
August 5, 2022
A CEACAM5-derived Peptide Activating CD8<sup>+</sup> Regulatory T Cells: A Future Option for Restoring Mucosal Homeostasis in Crohn's Disease?
Matthieu Allez
La Revue Du Praticien
|
February 24, 2005
[Crohn's disease and ulcerative colitis]
Marc Lémann, Matthieu Allez
La Revue Du Praticien
|
August 2, 2005
[Treatment strategies for inflammatory bowel disease]
Marc Lémann, Matthieu Allez
The American Journal of Gastroenterology
|
September 7, 2017
Response to Dhoble et al
Mathurin Fumery, Matthieu Allez
World Journal of Gastroenterology
|
June 3, 2010
Role of endoscopy in predicting the disease course in inflammatory bowel disease
Matthieu Allez, Marc Lémann
Current Drug Targets
|
March 10, 2010
Efficacy of anti-TNF in Crohn's disease: how does it work?
Yehuda Chowers, Matthieu Allez
Alimentary Pharmacology & Therapeutics
|
March 13, 2023
Editorial: severe colitis induced by targeted therapies in dermato-oncology beyond check point-inhibitors
Nassim Hammoudi, Matthieu Allez
The Lancet. Gastroenterology & Hepatology
|
February 15, 2025
Vedolizumab for prevention of recurrence of Crohn's disease
Nassim Hammoudi, Matthieu Allez
Current Opinion in Gastroenterology
|
June 4, 2015
Complications of biologics in inflammatory bowel disease
Paula Sousa, Matthieu Allez
Page
of 21